Inborn epimutations as markers of disease risk [ 2007 - 2009 ]

Research Grant

Researchers: A/Pr Catherine Suter (Principal investigator) ,  David Martin ,  Dr Ron Bova ,  Prof Richard Scolyer

Brief description DNA methylation is a mechanism used by many organisms, including humans, to keep certain regions of DNA inactive, i.e. in a state where they will not be read. Errors in this process may result in inappropriate inactivation of a gene, termed epimutation; this may occur even when no DNA sequence changes (i.e. mutations) are present. Some individuals are born with high levels of an epimutation that predisposes them to developing multiple cancers. Little is known about whether low levels of epimutations (only a portion of the body's cells affected) are important in development of sporadic (common) cancer. The aim of this project is to determine the levels of epimutations in the normal tissues of healthy individuals, and compare these with the levels in normal tissues of people who have had certain types of cancers. In doing this we hope to find out if low level epimutations contribute to the risk of developing sporadic cancer.

Funding Amount $AUD 344,185.05

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant